Does Naloxone Reverse SR-17018?

The short answer

That is the single most important point on this page: naloxone can work and still not be enough. Repeat doses may be needed, and emergency medical care is essential even if the person wakes up.

Can SR-17018 cause respiratory depression? Yes — despite what early reports claimed

You will still find pages online repeating the optimistic early claim that SR-17018 produces analgesia “without respiratory depression.” That framing is incomplete and can be dangerous if people treat it as a safety guarantee.

The original 2017 work helped launch interest in SR-17018 because it suggested a wider separation between analgesia and respiratory suppression than morphine or fentanyl in certain preclinical assays. But the story became more complicated as later work tested different routes, models, and interpretations of opioid receptor bias.

In particular, later oral mouse work found that SR-17018 can depress respiration when administered by the route most relevant to real-world human use. Other reanalyses challenged the simple “G-protein bias equals respiratory safety” explanation and argued that low intrinsic efficacy may explain much of the apparent safety margin.

Why naloxone still works at the receptor

There is a technical wrinkle worth understanding because it is easy to misread as “naloxone will not work.” SR-17018 has unusual receptor kinetics. Some studies describe SR-17018 and related compounds as producing wash-resistant or persistent mu-opioid receptor activation, meaning the receptor can remain in an activated signaling state longer than a conventional ligand might suggest.

That does not mean SR-17018 is naloxone-resistant. The persistent receptor state remains antagonist-reversible. In laboratory studies, naloxone and other opioid antagonists were able to reverse SR-17018-linked receptor activation.

The unusual kinetics mainly change the practical emergency problem: duration. The antidote can work, but the opioid effect may return after the antidote wears off.

The duration mismatch — the part that can kill people

This is not unique to SR-17018, but it is especially relevant to it.

Naloxone is short-acting. It can restore breathing within minutes in an opioid overdose, but its effect may last far less time than many opioids. Product labeling and public-health guidance both emphasize that respiratory depression can return and that repeat dosing may be needed.

SR-17018 appears to be longer-acting than the naloxone window. Its persistent receptor activation, slow offset behavior, and long-acting profile in animal work suggest that it can remain clinically relevant beyond a single reversal dose.

The practical consequences are direct:

• One dose of naloxone may not be enough. Be prepared for repeat dosing if breathing depression returns.
• Always call emergency services, even if naloxone works and the person wakes up.
• Do not assume the emergency is over because the person is conscious. With a longer-acting opioid, consciousness can return before risk is gone.
• Hospital-level monitoring matters. Longer-acting antagonists such as nalmefene exist and may be considered by clinicians, but that is not a home substitute for emergency care.

What to do in a suspected SR-17018 overdose

Signs of opioid overdose can include unresponsiveness, slow breathing, stopped breathing, gasping, gurgling, blue or gray lips or fingertips, limp body, and pinpoint pupils.

1. Call 911 or your local emergency number immediately. Say you suspect an opioid overdose.
2. Give naloxone if available. Use the intranasal or injectable product according to its instructions.
3. Support breathing. Start rescue breathing or CPR as trained if the person is not breathing normally.
4. If there is no response in 2–3 minutes, give another dose of naloxone. Use a new nasal spray or a new dose, and repeat as needed until responders arrive.
5. Stay with the person. Watch for breathing depression returning after they wake up.
6. Let EMS transport or seek hospital care. Monitoring needs to continue for hours, not minutes.

Naloxone will not harm someone who turns out not to have opioids in their system, and it will not reverse non-opioid causes of unconsciousness. If you are unsure, giving naloxone while calling emergency services is still the right harm-reduction response.

The polydrug reality

Most opioid deaths are not clean single-drug events. SR-17018 is discussed in the same online environments where benzodiazepines, alcohol, gabapentinoids, kratom alkaloids, and other opioids circulate.

Combining SR-17018 with any central-nervous-system depressant can sharply increase overdose risk. Naloxone reverses the opioid component, but it does not reverse alcohol, benzodiazepines, or other sedatives. In a mixed overdose, a person can remain dangerously sedated even after the opioid effect is partly blocked.

Waking someone up is the beginning of the emergency, not the end of it.

The takeaway

Naloxone works on SR-17018. That part is reassuring and supported by the pharmacology. But SR-17018 can suppress breathing, the early “no respiratory depression” story is not reliable as a safety rule, and the compound may outlast naloxone.

Those facts together mean the safe response to a suspected SR-17018 overdose is naloxone plus emergency services plus extended monitoring, never naloxone alone.

If you use SR-17018 or know someone who does: keep naloxone on hand, keep more than one dose, avoid using alone, avoid depressant combinations, and understand that a reversal can wear off.